Positron emission tomography11C-methionine and survival in patients with low-grade gliomas

Ribom, Dan; Eriksson, Anders; Hartman, Magdalena; Engler, Henry; Nilsson, Anna; Långström, Bengt; Bolander, Hans; Bergström, Mats; Smits, Anja

doi:10.1002/1097-0142(20010915)92:6<1541::aid-cncr1480>3.0.co;2-d

Cited by 153 publications

(80 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In many instances, the extent of increased 11 C-MET uptake is larger than that of contrast enhancement (33) and indicates tumor infiltration and tumor margins. Especially in low-grade gliomas, amino acid uptake is related to prognosis and survival (34,35). 11 C-MET PET therefore has special value in low-grade gliomas: for differentiation from nontumorous lesions, for detection of recurrences, for indicating changes in grade of progressing disease, and for potentially allowing a better prediction of prognosis.…”

Section: Petmentioning

confidence: 99%

Multimodality Assessment of Brain Tumors and Tumor Recurrence

Heiss¹,

Raab²,

Lanfermann³

2011

J Nucl Med

126

View full text Add to dashboard Cite

Learning Objectives: On successful completion of this activity, participants should be able to describe (1) the differences in the information obtained by various MRI and PET modalities and (2) the best combination of imaging procedures to detect brain tumors, to define the biologic activity or malignancy of a tumor, to validate therapeutic effects, and to differentiate between recurrent tumor and tissue necrosis.Financial Disclosure: The authors of this article have indicated no relevant relationships that could be perceived as a real or apparent conflict of interest. CME Credit: SNM is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing education for physicians. SNM designates each JNM continuing education article for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should claim only credit commensurate with the extent of their participation in the activity.For CE credit, participants can access this activity through the SNM Web site (http://www.snm.org/ce_online) through October 2012.Neuroimaging plays a significant role in the diagnosis of intracranial tumors, especially brain gliomas, and must consist of an assessment of location and extent of the tumor and of its biologic activity. Therefore, morphologic imaging modalities and functional, metabolic, or molecular imaging modalities should be combined for primary diagnosis and for following the course and evaluating therapeutic effects. MRI is the gold standard for providing detailed morphologic information and can supply some additional insights into metabolism (MR spectroscopy) and perfusion (perfusion-weighted imaging) but still has limitations in identifying tumor grade, invasive growth into neighboring tissue, and treatment-induced changes, as well as recurrences. These insights can be obtained by various PET modalities, including imaging of glucose metabolism, amino acid uptake, nucleoside uptake, and hypoxia. Diagnostic accuracy can benefit from coregistration of PET results and MRI, combining the high-resolution morphologic images with the biologic information. These procedures are optimized by the newly developed combination of PET and MRI modalities, permitting the simultaneous assessment of morphologic, functional, metabolic, and molecular information on the human brain. Brai n tumors are newly formed alterations of morphology, and for their diagnosis, therefore, CT or MRI is mandatory. These imaging modalities are essential for delineating the normal and pathologic anatomy and also for assessing vascular supply and impairment of the blood-brain barrier (BBB) (perfusion-weighted imaging; contrast enhancement). Additionally, MRI is capable of giving functional information on microstructural (diffusion-weighted imaging [DWI]), physiologic, and metabolic (MR spectroscopy [MRS]) changes of tumor tissues. PET and MRI provide physiologic, biochemical, and molecular information related to tumor metabolism, proliferation rate, invasiveness, and interaction with surrounding and remote areas-informati...

show abstract

Section: Petmentioning

confidence: 99%

Multimodality Assessment of Brain Tumors and Tumor Recurrence

Heiss¹,

Raab²,

Lanfermann³

2011

J Nucl Med

126

View full text Add to dashboard Cite

show abstract

“…91,92 In 80% of gliomas WHO II°[ 11 C]MET-uptake is greater than 1.5-fold of the normal brain tissue, 21 whereas glucose metabolism is reduced compared with gray matter. Most studies indicated that [ 11 C]MET-uptake is inversely correlated to prognosis, [93][94][95] 78,96 and exceeds the area of involvement depicted by Gd-enhanced MRI. 97 It should be pointed out that increased [ 11 C]MET uptake also depends on tumor type, with oligodendrogliomas accumulating more radiotracer than astrocytomas from the same histological grade.…”

Section: Imaging For Primary Diagnosismentioning

confidence: 99%

Imaging in neurooncology

et al. 2005

View full text Add to dashboard Cite

“…[10][11][12][13][14][15] In addition, MET uptake has been correlated with Mib-1 labeling index (LI), proliferating cell nuclear antigen, microvessel attenuation, and survival. [14][15][16][17][18] Mib-1 LI is a good marker to determine proliferative activity and has an important role in determining both malignant neoplasm and a patient's prognosis. To our knowledge, no study has been published regarding MET uptake and proliferative activity for patients with grade II glioma only.…”

mentioning

confidence: 99%

Analysis of¹¹C-methionine Uptake in Low-Grade Gliomas and Correlation with Proliferative Activity

Kato¹,

Shinoda²,

Oka³

et al. 2008

AJNR Am J Neuroradiol

View full text Add to dashboard Cite

BACKGROUND AND PURPOSE:The relationship of 11 C-methionine (MET) uptake and tumor activity in low-grade gliomas (those meeting the criteria for World Health Organization [WHO] grade II gliomas) remains uncertain. The aim of this study was to compare MET uptake in low-grade gliomas and to analyze whether MET positron-emission tomography (PET) can estimate tumor viability and provide evidence of malignant transformation.

show abstract

Positron emission tomography11C-methionine and survival in patients with low-grade gliomas

Cited by 153 publications

References 29 publications

Multimodality Assessment of Brain Tumors and Tumor Recurrence

Multimodality Assessment of Brain Tumors and Tumor Recurrence

Imaging in neurooncology

Analysis of¹¹C-methionine Uptake in Low-Grade Gliomas and Correlation with Proliferative Activity

Contact Info

Product

Resources

About

Positron emission tomography11C-methionine and survival in patients with low-grade gliomas

Cited by 153 publications

References 29 publications

Multimodality Assessment of Brain Tumors and Tumor Recurrence

Multimodality Assessment of Brain Tumors and Tumor Recurrence

Imaging in neurooncology

Analysis of11C-methionine Uptake in Low-Grade Gliomas and Correlation with Proliferative Activity

Contact Info

Product

Resources

About

Analysis of¹¹C-methionine Uptake in Low-Grade Gliomas and Correlation with Proliferative Activity